S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Biden’s Big Lie… (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Biden’s Big Lie… (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Biden’s Big Lie… (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Biden’s Big Lie… (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:MEDP

Medpace - MEDP Stock Forecast, Price & News

$184.13
+2.61 (+1.44%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$182.49
$185.06
50-Day Range
$174.31
$239.52
52-Week Range
$126.94
$241.48
Volume
175,698 shs
Average Volume
328,132 shs
Market Capitalization
$5.72 billion
P/E Ratio
25.15
Dividend Yield
N/A
Price Target
$235.50

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
27.9% Upside
$235.50 Price Target
Short Interest
Bearish
6.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.41mentions of Medpace in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.10%
From $7.66 to $8.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

110th out of 999 stocks

Commercial Physical Research Industry

6th out of 16 stocks


MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

Medpace (NASDAQ:MEDP) Lowered to "Hold" at StockNews.com
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Medpace Hldgs's Earnings: A Preview
Here’s Why Investors Hold Medpace Holdings (MEDP)
Medpace Holdings, Inc. (MEDP)
Why Medpace Holdings Jumped 41.5% This Week
Why Medpace Stock Soared Today
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
2/13/2023
Today
3/30/2023
Next Earnings (Confirmed)
4/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$235.50
High Stock Price Forecast
$238.00
Low Stock Price Forecast
$233.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$245.37 million
Pretax Margin
19.37%

Debt

Sales & Book Value

Annual Sales
$1.46 billion
Cash Flow
$8.69 per share
Book Value
$12.42 per share

Miscellaneous

Free Float
24,654,000
Market Cap
$5.72 billion
Optionable
Optionable
Beta
1.42

Key Executives

  • August James TroendleAugust James Troendle
    Chairman & Chief Executive Officer
  • Jesse J. GeigerJesse J. Geiger
    President
  • Susan E. Burwig
    Executive Vice President-Operations
  • Kevin M. BradyKevin M. Brady
    Chief Financial Officer & Treasurer
  • Brandon Ebken
    Chief Information Officer













MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2023?

3 brokerages have issued 12-month target prices for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $238.00. On average, they anticipate the company's share price to reach $235.50 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2023?

Medpace's stock was trading at $212.41 at the beginning of 2023. Since then, MEDP stock has decreased by 13.3% and is now trading at $184.13.
View the best growth stocks for 2023 here
.

Are investors shorting Medpace?

Medpace saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,490,000 shares, an increase of 23.1% from the February 28th total of 1,210,000 shares. Based on an average daily volume of 318,100 shares, the short-interest ratio is currently 4.7 days. Approximately 6.3% of the shares of the stock are sold short.
View Medpace's Short Interest
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023.
View our MEDP earnings forecast
.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, February, 13th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.78 by $0.34. The business earned $394.10 million during the quarter, compared to the consensus estimate of $386.09 million. Medpace had a net margin of 16.81% and a trailing twelve-month return on equity of 60.42%. The business's revenue was up 27.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 earnings per share.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of $7.53-$8.14 for the period, compared to the consensus estimate of $7.72. The company issued revenue guidance of $1.69 billion-$1.75 billion, compared to the consensus revenue estimate of $1.70 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fuller & Thaler Asset Management Inc. (3.02%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.88%), Boston Trust Walden Corp (1.76%), Riverbridge Partners LLC (1.47%) and Millennium Management LLC (1.45%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $184.13.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $5.72 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.32 on an earnings per share basis.

How many employees does Medpace have?

The company employs 5,200 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 3/30/2023 by MarketBeat.com Staff